Previous 10 | Next 10 |
PRINCETON, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT) today announced it has acquired Applied BioMath, an industry-leader in providing model-informed drug discovery and development support to help accelerate and de-risk therapeutic research and development (R&D). Tog...
2023-12-10 13:04:00 ET More on AbCellera Biologics, Absci, etc. AbCellera: Difficult 2023 Suggests Business Model Should Pivot In 2024 Buy AbCellera Biologics's Revolutionizing AI-Powered Drug Development Platform Certara, Inc. 2023 Q3 - Results - Earnings Call Prese...
Indicative Terms for up to US$175m in a potential UKEF (UK Export Credit Agency) Supported Project Financing Banco Santander S.A. appointed as Mandated Lead Arranger due to extensive experience in ECA and Resources sector financing with a significant presence Brazil (All numbers report...
Q3 Production of 10,082Gold Equivalent Ounces("GEO") Q3 results impacted by severe weather conditions Operations back on track in October and November with shipments of approximately 5,600 and 5,470 GEO, respectively Minera Don Nicolas ("MDN") Expansion Capital Expenditure program ...
PRINCETON, N.J., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the introduction of Simcyp™ Biopharmaceutics software. It is designed for use by biopharmaceutic, formulation, and CMC scientists to aid in formulating co...
Indicative Terms for up to US$598m in a potential UKEF (UK Export Credit Agency) Supported Project Financing Company in final stages of appointing the Mandated Lead Arranger for Monte Do Carmo, Brazil (All numbers reported in US dollars) TORONTO, ON / ACCESSWIRE / November 21, 2023...
2023-11-08 22:41:08 ET Certara Inc. (CERT) Q3 2023 Earnings Conference Call November 08, 2023 05:00 PM ET Company Participants David Deuchler - Investor Relations William Feehery - Chief Executive Officer John Gallagher - Chief Financial Officer Conference ...
2023-11-08 16:59:06 ET Certara press release ( NASDAQ: CERT ): Q3 Non-GAAP EPS of $0.11. Revenue of $85.6M (+1.1% Y/Y). Expects Full year 2023 revenue to be in the range of $345 million to $360 million. Expects Full year 2023 adjusted diluted earnings per share to ...
PRINCETON, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the third quarter of fiscal year 2023. Third Quarter Highlights: Revenue was $85.6 million, compared to $84.7 million in th...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-16 14:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Combined organization brings broader predictive capabilities to drug discovery at scale Reiterates full year 2024 guidance RADNOR, Pa., July 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced it has signed...
RADNOR, Pa., July 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2024 after the market close on Tuesday, August 6 th , 2024. Company management will...